Published in J Vet Intern Med on March 25, 2016
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell (1995) 14.90
The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene (2007) 10.08
Involvement of the bcl-2 gene in human follicular lymphoma. Science (1985) 8.19
Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol (1993) 3.09
Apoptosis-based therapies for hematologic malignancies. Blood (2005) 2.77
Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol (1995) 2.48
Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol (1995) 2.04
Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans--man and his best friend share more than companionship. Chromosome Res (2008) 1.87
Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc (1994) 1.77
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood (2002) 1.63
Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood (1998) 1.61
Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Vet J (2004) 1.54
Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res (2005) 1.31
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica (2012) 1.21
High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol (2010) 1.14
Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. Cancer Res (2013) 1.14
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochim Biophys Acta (2015) 1.05
Molecular profiling reveals prognostically significant subtypes of canine lymphoma. Vet Pathol (2012) 1.03
Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival. Vet Pathol (2013) 1.02
Class II major histocompatibility complex expression and cell size independently predict survival in canine B-cell lymphoma. J Vet Intern Med (2011) 0.91
BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation. J Pathol (2003) 0.90
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood (2014) 0.90
Evaluation of molecular markers in canine mammary tumors: correlation with histological grading. Oncol Res (2009) 0.89
Lymphoma immunophenotype of dogs determined by immunohistochemistry, flow cytometry, and polymerase chain reaction for antigen receptor rearrangements. J Vet Intern Med (2013) 0.89
Flow cytometric characterization and clinical outcome of CD4+ T-cell lymphoma in dogs: 67 cases. J Vet Intern Med (2014) 0.88
Correlation of seven biological factors (Hsp90a, p53, MDM2, Bcl-2, Bax, Cytochrome C, and Cleaved caspase3) with clinical outcomes of ALK+ anaplastic large-cell lymphoma. Biomed Environ Sci (2011) 0.86
Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. Am J Hematol (2003) 0.86
Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma. J Vet Med Sci (2010) 0.85
Canine T-zone lymphoma: unique immunophenotypic features, outcome, and population characteristics. J Vet Intern Med (2014) 0.85
Reading between the lines: molecular characterization of five widely used canine lymphoid tumour cell lines. Vet Comp Oncol (2011) 0.84
Identification of altered MicroRNA expression in canine lymphoid cell lines and cases of B- and T-Cell lymphomas. Genes Chromosomes Cancer (2011) 0.83
Flow cytometry in veterinary oncology. Vet Pathol (2010) 0.81
Predictors of long-term survival in dogs with high-grade multicentric lymphoma. J Am Vet Med Assoc (2011) 0.79
Evaluation of a B-cell leukemia-lymphoma 2-specific radiolabeled peptide nucleic acid-peptide conjugate for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma. Am J Vet Res (2012) 0.78
bcl-2 and MIB-1 labeling indexes in cats with lymphoma. J Vet Intern Med (2002) 0.78
Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas. Ann Hematol (2006) 0.78
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. Haematologica (2015) 0.76
The immunosignature of canine lymphoma: characterization and diagnostic application. BMC Cancer (2014) 0.76
Immunohistochemical expression study of proapoptotic BH3-only protein bad in canine nonneoplastic tissues and canine lymphomas. Vet Pathol (2013) 0.76
The value of immunohistochemical expression of BAX in formulating a prognosis for canine cutaneous mast cell tumours. J Comp Pathol (2011) 0.76